February 19, 2013 – (Victoria, B.C.) Responding to the cardiovascular device industry’s demand for testing equipment that can accommodate larger prosthetic heart valves and multiple cardiovascular devices at one time, ViVitro is pleased to announce the availability of the ViVitro Real-Time Wear Tester (RWT). Using the proven power and reliability of the ViVitro SuperPump, the ViVitro RWT promises to become one of the industry’s most sought after pieces of testing equipment for the testing of multiple and larger cardiovascular devices such as heart valve replacements, venal replacements, cardiac patches, and occluder devices. (more…)
April 19, 2012 – Victoria, B.C. – ViVitro Labs is honored to be the recipient of the 2012 Business Excellence Award for Professional Services, sponsored by the Business Examiner. Recognizing a company that demonstrates achievements in its industry and contributes to the local business community’s recognition and prosperity, this award reflects the strength and combined expertise of the ViVitro team. ViVitro Labs enjoys a global presence and world renown for their prosthetic heart valve test equipment, laboratory services, and custom engineering services that enable the industry’s most advanced cardiovascular devices to be tested for safety, efficacy, and regulatory approval. Complete press release.
January 25, 2012 – Victoria, B.C. – ViVitro Labs Inc., a global provider of cardiovascular device testing equipment and laboratory services, announces that its Laboratory Services headquartered in Victoria, B.C. has been accredited by the American Association for Laboratory Accreditation (A2LA) to perform Laboratory testing for ISO 5840 Cardiovascular Implants – Cardiac Valve Prostheses Annex L and M in accordance with ISO/IEC 17025:2005, the most recognized standard for competence of testing in the industry. Complete press release.
The accreditation confirms ViVitro Labs commitment to meeting the highest quality standards and regulatory requirements to perform testing on heart valves to the ISO 5840 standard. The increasing challenges and demands on medical device manufacturers to evaluate heart valves for haemolytic and thrombogenic potential by assessment of flow fields, to determine hydrodynamic performance and assess durability have never been so achievable.
Medical devices are subject to the some of the highest governmental regulations.
“ViVitro Labs Granted Accreditation and recognizing a single quality benchmark, ISO 17025 provides a highly recognized global standard for laboratory testing compliance,” states David Mester, General Manager of ViVitro Labs, “We welcomed the opportunity to prove our compliance, believing that should be a basic tenet for all in our industry, and we’re pleased that A2LA has recognized our quality system.”
ViVitro Labs has taken the first step to harmonizing ISO standards by applying a more rigorous and uniformed standard for competence of testing for the assessment of heart valve replacements including transcatheter heart
valves governed by the ISO 5840 standard.
About ViVitro Labs
ViVitro Labs Inc. offers industry leading prosthetic heart valve test equipment and laboratory testing, consulting and engineering services. For over 25 years, ViVitro has been known as a trusted source of quality devices and
services that empower our clients to carry out world-leading research, develop innovative products, and demonstrate regulatory compliance.
September 13th, 2011 – Victoria, B.C. – ViVitro Labs Inc., a global provider of cardiovascular device testing equipment and laboratory services, announces the release of the next generation of their legendary SuperPump, the SuperPump AR. Assisted by their affiliate company, Starfish Medical Inc., the ViVitro SuperPump, the world’s most widely used and accurate physiological mimicking positive displacement pump, has been redesigned and enhanced with the latest technology available. The ViVitro SuperPump AR is the first in a series of advanced prosthetic heart valve and other cardiovascular device testing equipment being developed by ViVitro. Complete press release.
Victoria, B.C. – ViVitro Labs Inc. and Medical Implant Mechanics LLC (MIM) today announced a partnership to provide comprehensive product testing services for the cardiovascular device industry. Recognizing that current medical device development employs a combination of novel materials and complex design, the new partnership affords the collaborative expertise required to provide meaningful advice and quality results. Addressing the challenge to attain regulatory approval for the latest advances in product development, the combined experience and knowledge base of ViVitro Labs and Medical Implant Mechanics offers a proven and significant means to expedite the process. Complete press release.
March 3, 2009 – Victoria, B.C. – StarFish Medical today announced that it has purchased the product lines of ViVitro Systems Inc., a 25-year old, privately held Victoria company. ViVitro offers industry leading prosthetic heart valve test equipment and related testing and consulting services worldwide. The agreement ensures StarFish Medical Acquires the Assets of ViVitro, provides continuity for the company’s customers and holds a promising future for the further development of the product line and testing services. ViVitro equipment will continue to be sold under the current brand. Complete press release.
StarFish president, Scott Phillips, sees the deal as a perfect fit, since it leverages the core expertise of StarFish in medical device development and manufacturing and builds on the good reputation ViVitro has established over the years. The ViVitro assets will be rolled into a new wholly-owned subsidiary of StarFish. Founding partners David Walker, Ph.D. and Larry Scotten, Dipl. T., will provide product support during the transition and will continue offering research and testing services for a limited time.
StarFish Medical intends to evolve the current product line and to more actively market it to worldwide clients from medical device companies to universities and regulatory bodies. The heart valve market and demand for such products is continually growing, with new countries coming on line. StarFish sees potential increased demand for testing services, especially with the Food and Drug Administration in the U.S. asking for more testing than ever.
With an aging population in developed countries and rapid expansion of healthcare systems in developing nations, the cardiovascular healthcare sector is expanding substantially. Medical devices are estimated to grow 5% yearly in the United States, their largest world market, over the next five years (Business Monitor International).
The two partners originally built the ViVitro test equipment to evaluate a new valve developed at the Royal Jubilee Hospital’s Cardiac Development Lab in the mid-1970s. The first prototype of their laboratory pump and model heart was constructed using a VW piston. From there the partners evolved it into the sophisticated, market leading test equipment it has become today. Scotten and Walker welcome StarFish Medical taking over their products and services, since the two companies have developed a close working relationship. StarFish has been assembling ViVitro equipment for two years and is currently in production for new orders.
ViVitro has customers in twenty countries including the U.S.A., Canada, Australia, Brazil, Japan, Singapore, and several European countries.
About ViVitro Systems
ViVitro Systems Inc. is a privately held company that was founded out of research at Royal Jubilee Hospital in 1983 by David Walker, Ph.D. and Lawrence Scotten, Dipl.T. ViVitro makes two main products, a fatigue tester for
assessing the durability of prosthetic mechanical and biological heart valves, and a laboratory model heart flow tester used primarily in medical research. The company also offers prosthetic heart valve testing services.